Abstract:Background: The residual drug carriers on drug‐eluting stents (DES) surfaces are considered to be one of the most significant reasons causing late thrombosis. There is no documented data currently available on the safety/benefit profile beyond 6 months of EXCEL stent, a novel sirolimus‐eluting stent with biodegradable polymer coating, in treating patients with coronary artery disease (CHD). Objective: To evaluate the long‐term efficacy and safety of EXCEL stent on treating CHD patients. Methods: Between February and March 2006, a consecutive cohort of complex patients treated with the EXCEL stent was prospectively enrolled in this single‐center registry. Antiplatelet protocol was 6‐month dual antiplatelet therapy with clopidogrel and aspirin followed by aspirin alone indefinitely. The primary outcome was major adverse cardiac events (MACE) at 12 months. Secondary outcomes included in‐segment and in‐stent late lumen loss and binary restenosis rate measured by quantitative coronary angiography (QCA) analysis at 8 months postindex PCI procedure. Results: A total of 100 patients with 153 lesions were included in this analysis. Most lesions (83.0%) were classified as complex (B2/C). At 12 months, four patients (4.0%) experienced MACE, which were four target‐lesion revascularizations due to in‐stent restenosis (ISR). All patients received follow‐up up to 24 ± 0.4 months and no cardiac death, MI, and in‐stent thrombosis occurred during the 6 months of dual antiplatelet therapy or the subsequent 15 months of aspirin treatment alone. QCA analysis of 112 lesions from 75 patients showed 3.6% (4/112) in‐stent lesion restenosis, 5.4% (6/112) in‐segment lesion restenosis, 0.12 ± 0.34 mm in‐stent late lumen loss, and 0.08 ± 0.35 mm in‐segment late lumen loss. Conclusions: In this single‐center experience with complex patients and lesions, the EXCELTM stent implantation with 6‐month dual antiplatelet treatment proved to markedly reduce the incidence of 24‐month ISR and MACE. These preliminary findings require further validation by large scale, randomized trials. © 2008 Wiley‐Liss, Inc.

Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: Three-year outcomes of the CREATE (multi-center registry of EXCEL biodegradable polymer drug eluting stents) study

Safety And Efficacy Of Biodegradable-Polymer Coated Sirolimus-Eluting Stents In Real-World Practice: 18-Month Clinical And 9-Month Angiographic Outcomes

A New Generation of Biodegradable Polymer-Coated Sirolimus-Eluting Stents for the Treatment of Coronary Artery Disease: Final 5-Year Clinical Outcomes from the CREATE Study.

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

Clinical Efficacy and Safety of Biodegradable Polymer‐based Sirolimus‐eluting Stents in Patients with Diabetes Mellitus Insight from the 4‐year Results of the Create Study

GW29-e2015 Primary Endpoint Outcomes of A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (mistent® System) Compared to TIVOLI in the Treatment of Patients with Coronary Heart Disease

Efficacy and Safety of A Second Generation Biodegradable-Polymer Sirolimus-Eluting Stent: One Year Results of The CREDIT 2 Trial.

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.

Five Years Sustained Clinical Safety and Efficacy of an Abluminal Biodegradable-Polymer Coated Sirolimus-Eluting Stent: A Randomized Controlled Trial

Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trial.

First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

A novel biodegradable polymer-coated sirolimus-eluting stent: the 1-year results of the HELIOS registry

Safety and Efficacy of a Novel Abluminal Groove‐filled Biodegradable Polymer Sirolimus‐eluting Stent for the Treatment of De Novo Coronary Lesions: Two‐year Results from a Prospective Patient‐level Pooled Analysis of TARGET Trials

TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials

Real Polymer-Free Sirolimus- and Probucol-Eluting Versus Biodegradable Polymer Sirolimus-Eluting Stents for Obstructive Coronary Artery Disease: Dkplus-Wave 1, A Multi-Center, Randomized, Prospective Trial

Randomized Clinical Trial Comparing Abluminal Biodegradable Polymer Sirolimus-Eluting Stents With Durable Polymer Sirolimus-Eluting Stents: Nine Months Angiographic And 5-Year Clinical Outcomes

Efficacy and Safety of a Biodegradable Polymer Cobalt-Chromium Sirolimus-Eluting Stent (EXCEL2) in Treating De Novo Coronary Artery Disease: A Pooled Analysis of the CREDIT II and CREDIT III Trials. DOI: 10.1002/ccd.26887

Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study